UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For
the month of July 2025
Commission
File Number: 001-41677
CytoMed
THerapeutics Limited
(Translation
of registrant’s name into English)
1
Commonwealth Lane
#08-22
Singapore
149544
(Address of principal executive office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form
20-F ☒ Form 40-F ☐
On
May 1, 2025, the Compensation Committee and the Board of Directors of CytoMed Therapeutics Limited (the “Company”) approved
the issuance of ordinary shares to the following individuals as compensation for their continued service to the Company:
| (i) | 11,250
ordinary shares to Dr. Lucas Luk Tien Wee, Chief Clinical Officer, subject to a six-month
restriction period from the date of issuance; |
| (ii) | 25,781
ordinary shares to Ms. Goh Yvonne, Chief Financial Officer, subject to a six-month restriction
period from the date of issuance; |
| (iii) | 25,781
ordinary shares to Ms. Tan Yoong Ying, Chief Corporate Officer, subject to a six-month restriction
period from the date of issuance; and |
| (iv) | 469
ordinary shares to Dr. Yew Chak Hua, Independent Director, subject to a six-month restriction
period from the date of issuance. |
On
July 1, 2025, the Company entered into supplemental agreements to the existing appointment agreements with each of the above individuals
to formally effect the grant of the respective ordinary shares.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
| |
CytoMed
Therapeutics Limited. |
| |
|
|
| Date:
July 3, 2025 |
By: |
/s/
Choo Chee Kong |
| |
Name: |
Choo
Chee Kong |
| |
Title: |
Chairman
& Director |
